BTS Partners 2026
Gold Partners
Astellas Pharma Limited
astellas.eu
On the forefront of healthcare change, Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.
Astellas Pharma is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. We strive to develop therapies that are first-in-class and best-in-class. Treatments that offer patients and their doctors genuinely new options for improving care.
Chiesi Limited
chiesi.uk.com
Chiesi Limited are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Special Care and Rare Diseases.
Transplantation is an area to which Chiesi are committed to developing further as part of a growing Special Care portfolio.
Chiesi are proud to play a part in helping patients protect their gift of life, and aim to be an important, reliable partner for transplant clinicians and patient organisations across the UK
UK-TR-2200001 January 2022
The BTS would like to thank Chiesi for supporting our green initiatives
Paragonix
www.paragonix.com.
Paragonix Technologies, a Getinge company, is redefining how donor organs are protected and delivered, setting a new standard of care for transplantation worldwide.
Built on the belief that every donated organ deserves the highest level of precision and respect, Paragonix partners with transplant centers to improve outcomes through clinically proven preservation technologies and expert, hands-on procurement support.
Combined with real-time digital monitoring, transparent data sharing, and the world’s largest preservation-focused clinical registries, Paragonix aims to deliver every possible advantage to healthcare providers and patients alike.
iMDx
imdxinc.com
Insight Molecular Diagnostics Inc. (iMDx) is dedicated to advancing precision medicine in transplantation. Our mission is to democratize access to cutting-edge diagnostic solutions by making precision medicine more widely available through both clinical testing and research-driven collaborations. By empowering physicians, researchers, and patients with clear, actionable insights, we help drive informed decision-making and better health outcomes.
Behind every test is a person—a patient awaiting answers and a physician seeking the best path forward. This profound responsibility fuels our commitment to innovation. We develop diagnostic solutions that are not only scientifically advanced but also practical and accessible, ensuring they deliver clear, reliable results when they matter most.
Through partnerships with leading physicians, institutions, and researchers worldwide, we push the boundaries of scientific discovery. Our research-use-only (RUO) solutions enable laboratories to bring tests in-house, accelerating progress in transplant management, while our IVD products will enable local patient management and value capture.
Hansa Biopharma
hansabiopharma.com
Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.
The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
This conditional approval was also granted by the MHRA in January 2021. Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.
Silver Partners
Sandoz
sandoz.uk.com
Sandoz is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading generics company and our broad portfolio of high-quality medicines covers major therapeutic areas.
UK | January 2025 | MLR-0667-UK
Takeda
takeda.com/en-gb
Takeda Pharmaceutical Company Limited is headquartered in Japan and is a global, values-based, R&D-driven biopharmaceutical leader. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. Our employees are committed to improving quality of life for patients.
Additional information about Takeda UK Ltd. is available through its corporate website
The BTS would like to thank Takeda UK for supporting our green initiatives
